Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Royalty Pharma has reported Intangibles for 3 years, with the latest figure at $5.7 million in Q4 2021.

• Quarterly Intangibles fell 80.22% year-over-year to $5.7 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.7 million (down 80.22% YoY) and the FY2021 annual result came in at $5.7 million, down 80.22% from the prior year.
• Intangibles retreated to $5.7 million in Q4 2021 per RPRX's latest filing, from $11.5 million in the prior quarter.
• Over five years, Intangibles peaked at $51.7 million in Q4 2019 and troughed at $5.7 million in Q4 2021.
• A 3-year average of $26.6 million and a median of $25.8 million in 2020 frame the typical range for Intangibles.
• The sharpest annual moves came in 2020 and 2021: Intangibles sank 44.58% in 2020, then tumbled 80.22% in 2021.
• Over 3 years, Intangibles stood at $51.7 million in 2019, then tumbled by 44.58% to $28.7 million in 2020, then sank by 80.22% to $5.7 million in 2021.
• According to Business Quant data, Intangibles over the past three periods registered $5.7 million, $11.5 million, and $17.3 million for Q4 2021, Q3 2021, and Q2 2021 respectively.